ponatinib

a pan-Bcr-Abl protein kinase Inhibitor; structure in first source

Also Known As:

3-(2-(imidazo(1,2-b)pyridazin-3-yl)ethynyl)-4-methyl-N-(4-((4-methylpiperazin-y-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide; AP 24534; AP-24534; AP24534; Iclusig; ponatinib hydrochloride

Networked: 465 relevant articles (63 outcomes, 67 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - ponatinib: 465
  - Pyridazines: 11
    - ponatinib: 465

Experts

1.	Kantarjian, Hagop: 18 articles (09/2022 - 11/2012)
2.	Jabbour, Elias: 17 articles (09/2022 - 04/2015)
3.	Ravandi, Farhad: 13 articles (05/2022 - 04/2015)
4.	Cortes, Jorge: 13 articles (01/2022 - 06/2013)
5.	Rivera, Victor M: 12 articles (01/2022 - 11/2009)
6.	Garcia-Manero, Guillermo: 11 articles (09/2022 - 11/2015)
7.	Breccia, Massimo: 11 articles (01/2021 - 01/2016)
8.	Jain, Nitin: 10 articles (05/2022 - 11/2015)
9.	Kantarjian, Hagop M: 10 articles (05/2022 - 06/2013)
10.	Druker, Brian J: 10 articles (01/2020 - 11/2009)

Related Diseases

1.	Philadelphia Chromosome 01/01/2020 - "Ponatinib has proven to be effective in adults with Philadelphia chromosome-positive leukaemias, but data in paediatrics are scarce. " 01/01/2020 - "Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study." 01/01/2023 - "Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients." 10/01/2019 - "Successful treatment with ponatinib for central nervous system relapse of Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia." 01/01/2018 - "As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures ponatinib (Inclusig®; Incyte Corporation) to submit evidence for the clinical and cost effectiveness for previously treated chronic myeloid leukaemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). "
2.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/01/2020 - "Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes." 01/01/2018 - "Low-Dose Ponatinib in Intolerant Chronic Myeloid Leukemia Patients: A Safe and Effective Option." 12/01/2019 - "The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission." 03/30/2019 - "[Clinical characteristics of chronic myeloid leukemia with T315I mutation and the efficacy of ponatinib]." 11/01/2023 - "This study explores the therapeutic potential of targeting CXCR2 in patients afflicted with ponatinib-resistant chronic myeloid leukemia (CML). "
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/2021 - "Durable Molecular Remission in an Elderly Patient Affected by Relapsed Ph'+ Acute Lymphoblastic Leukemia with T315I and Concomitant p190 and p210 Expression Achieved by Inotuzumab and Ponatinib." 01/01/2018 - "The median age in our cohort was 43 years (range, 9-82 years), significantly younger than expected for patients with relapsed or refractory CML and 20 years younger than the median age of patients who participated in the PACE (ponatinib Philadelphia-positive acute lymphoblastic leukemia and CML evaluation) trial. " 01/01/2023 - "Ponatinib plus Hyper-CVAD yields a five-year overall survival of 73% in patients with Philadelphia-positive acute lymphoblastic leukemia. " 12/01/2022 - "A Rare Case of p190 BCR-ABL B-cell Acute Lymphocytic Leukemia With Excellent Response to Hyper-CVAD and Ponatinib." 01/01/2022 - "Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia."
4.	Neoplasms (Cancer) 11/01/2017 - "Taken together, the regional differences in free drug exposure across the intracranial tumor may be responsible for compromising efficacy of ponatinib in orthotopic GBM6." 11/09/2018 - "In this review we report the most recent preclinical and clinical studies on ponatinib in cancers other than CML, with the aim of giving a complete overview of this interesting compound." 02/10/2023 - "However, Ponatinib itself did not have any direct toxic effect on cancer cells in vitro. " 02/10/2023 - "Furthermore, Ponatinib also reduced the expression of PD-L1 in tumors and increased the T-cell population. " 02/10/2023 - "Ponatinib was found to be more efficient in delaying tumor growth than the anti-PD-L1 antibody. "
5.	Leukemia 07/01/2022 - "Ponatinib may be safe and effective in pediatric patients with Ph+ leukemia." 08/21/2023 - "Subsequently was started maintenance with ponatinib: at last follow-up, the patient persisted in leukemia-free status. " 01/01/2022 - "Real-life incidence of thrombotic events in leukemia patients treated with ponatinib." 01/01/2022 - "Aim: To synthesize new analogues of ponatinib and evaluate anti-leukemia cells and cytotoxicity. " 01/01/2022 - "Synthesis of ponatinib analogues as novel inhibitors of leukemia stem cells."

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors
2.	Dasatinib (BMS 354825)
3.	Imatinib Mesylate (Gleevec)
4.	nilotinib
5.	Phosphotransferases (Kinase)
6.	blinatumomab
7.	bosutinib
8.	Phytochemicals
9.	Gossypol
10.	asciminib

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Hematopoietic Stem Cell Transplantation
4.	Stem Cell Transplantation
5.	Salvage Therapy